Company profile
Pathios Therapeutics
Pathios Therapeutics Limited is a UK company with status active founded in 2017 based in South East England.
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
AA | Transaction MzUyNzMxMDk4N2FkaXF6a2N4
Published 19 Jun 2026 11:47
SH01 | Transaction MzUyMzI1MzU5N2FkaXF6a2N4
Published 22 May 2026 10:34
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0MDg0OTgyM2FkaXF6a2N4
Published 24 Oct 2024 02:07
AA | Transaction MzQzNzQ3OTY0MmFkaXF6a2N4
Published 27 Sep 2024 08:02
Company registered at Companies House
1 Sep 2024 to 28 Feb 2026
Pathios Therapeutics is a drug discovery company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, and part of the M:M Bio (Molecule 2 Medicine) ecosystem, the company is founded upon a deep understanding of the biology of tumour-associated macrophages (TAMs). There ...
1 Dec 2022 to 29 Feb 2024
**Pathios Therapeutics** specialise in identifying and developing molecules that alter the signalling of a specialised cell-surface receptor in the immune system that detects changes in the local pH called GPR65\. Pathios has a deep understanding of GPR65 and develop drugs that block or 'switch off' the signalling of this receptor to treat cancers. Pathio...
1 Dec 2021 to 31 Jan 2022
**Pathios Therapeutics** is a company that specialises in developing molecules that alter the signalling of cell-surface receptors in the immune system that detect changes in pH. The company has particular expertise in the understanding of a receptor called GPR65 and is currently seeking to make drugs that block or 'switch off' the signalling of this rece...
1 Sep 2020 to 31 May 2022
**Pathios Therapeutics** is a company that specialises in developing molecules that alter the signalling of cell-surface receptors in the immune system that detect changes in pH. The company has particular expertise in the understanding of a receptor called GPR65 and is currently seeking to make drugs that block or 'switch off' the signalling of this rece...
